Genetic Technologies

Genetic Technologies Debt

The Debt of Genetic Technologies (GTG.AX) as of Oct 27, 2026 is 875,189.00 AUD. In the previous year, Debt was 532,850.00 AUD — a change of 64.25% (higher).

Debt

875,189.00AUD

YoY

64.25%

Last updated:

In 2024, Genetic Technologies's total debt was 875,189.00 AUD, a 64.25% change from the 532,850.00 AUD total debt recorded in the previous year.

The Genetic Technologies Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
3,377.00 AUD
Jan 1, 2018
3,505.00 AUD
Jan 1, 2019
481,788.00 AUD
Jan 1, 2020
481,788.00 AUD
Jan 1, 2021
204,038.00 AUD
Jan 1, 2022
652,530.00 AUD
Jan 1, 2023
532,850.00 AUD
Jan 1, 2024
875,189.00 AUD
The Genetic Technologies Debt history
YEARDebtYoY
875,189.00AUD+64.25%
532,850.00AUD-18.34%
652,530.00AUD+219.81%
204,038.00AUD-57.65%
481,788.00AUD0.00%
481,788.00AUD+13,645.73%
3,505.00AUD+3.79%
3,377.00AUD-19.77%
4,209.00AUD-83.16%
25,000.00AUD-99.00%
2.50 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Technologies Stock analysis

What does Genetic Technologies do? Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies is one of the most popular companies on Eulerpool.

Debt Details

Understanding Genetic Technologies's Debt Structure

Genetic Technologies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Genetic Technologies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Genetic Technologies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Genetic Technologies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Genetic Technologies stock

Debt of Genetic Technologies is 875,189.00 AUD in 2024.

Debt of Genetic Technologies changed from 532,850.00 AUD to 875,189.00 AUD, representing a 64.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Genetic Technologies since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Genetic Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genetic Technologies

All Key Metrics — Genetic Technologies